Table 4 Spirometry outcomes in tiotropium and placebo groups according to different threshold criteria for bronchodilator responsiveness.†
From: Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial
A | Criterion A (∆ % Predicted FEV1≥12% and ≥200 mL) | Criterion B (∆ % Predicted FEV1≥15%) | Criterion C (∆ % Predicted FEV1≥10%) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Nonresponder | Responder | Nonresponder | Responder | Nonresponder | Responder | |||||||
Prebronchodilator | ||||||||||||
Difference in FEV1 at 4 years (mL)* | 76 (54, 98) | 98 (77, 119) | 97 (69, 124) | 83 (65, 101) | 78 (58, 97) | 105 (81, 130) | ||||||
Difference in FVC at 4 years (mL)* | 134 (89, 178) | 195 (153, 236) | 143 (92, 194) | 179 (140, 217) | 139 (99, 179) | 213 (165, 260) | ||||||
B | Criterion A (∆ % Predicted FEV 1 ≥12% and ≥200 mL) | Criterion B (∆ % Predicted FEV 1 ≥15%) | Criterion C (∆ % Predicted FEV 1 ≥10%) | |||||||||
Nonresponder | Responder | Nonresponder | Responder | Nonresponder | Responder | |||||||
Tio | Placebo | Tio | Placebo | Tio | Placebo | Tio | Placebo | Tio | Placebo | Tio | Placebo | |
Rate of change in FEV1 (mL/year)† | ||||||||||||
Prebronchodilator | -32 ± 2 | -31 ± 2 | -29 ± 2 | -29 ± 2 | -35 ± 2 | -38 ± 2 | -28 ± 2 | -26 ± 2 | -32 ± 2 | -32 ± 2 | -28 ± 2 | -28 ± 2 |
Postbronchodilator | -37 ± 2 | -37 ± 2 | -43 ± 2 | -47 ± 2 | -38 ± 2 | -42 ± 2 | -42 ± 2 | -43 ± 2 | -39 ± 2 | -39 ± 2 | -43 ± 2 | -47 ± 2 |